NVO - Novo Nordisk A/S

NYSE - Nasdaq Real Time Price. Currency in USD
46.97
-0.23 (-0.49%)
As of 3:18PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close47.20
Open47.18
Bid46.9500 x 900
Ask46.9600 x 800
Day's Range46.91 - 47.30
52 Week Range41.23 - 58.37
Volume1,034,732
Avg. Volume1,560,872
Market Cap111.524B
Beta (3Y Monthly)0.94
PE Ratio (TTM)19.08
EPS (TTM)2.4620
Earnings DateN/A
Forward Dividend & Yield1.27 (2.61%)
Ex-Dividend Date2018-08-17
1y Target Est49.41
Trade prices are not sourced from all markets
  • 3 Top Diabetes Stocks to Watch in January
    Motley Fool18 hours ago

    3 Top Diabetes Stocks to Watch in January

    Diabetes and related conditions affect over 100 million Americans and many more worldwide. Here are three companies helping fight that disease.

  • 6 Bargain Stocks With Positive Earnings Growth Estimates
    GuruFocus.com2 days ago

    6 Bargain Stocks With Positive Earnings Growth Estimates

    According to the GuruFocus All-in-One Screener, the following stocks are trading at a discount and have positive three- to five-year future earnings estimates. Warning! GuruFocus has detected 5 Warning Sign with SCI. The discounted cash flow calculator gives the stock a fair value of $46.95 per share, suggesting it has an 11% margin of safety.

  • CNBC2 days ago

    House Democrats launch drug-pricing probe into a dozen major health-care companies

    AbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Novartis, Novo Nordisk, Pfizer, Sanofi and Teva Pharmaceuticals received letters seeking detailed information and documents about the companies' pricing practices.

  • 5 Reasons Why Investors Should Buy Novo Nordisk (NVO) in 2019
    Zacks5 days ago

    5 Reasons Why Investors Should Buy Novo Nordisk (NVO) in 2019

    Novo Nordisk (NVO) has a strong presence in the Diabetes care market and its top line is driven by strong performance of products like Victoza.

  • J&J raises U.S. prices on around two dozen drugs
    Reuters6 days ago

    J&J raises U.S. prices on around two dozen drugs

    Johnson & Johnson raised U.S. prices on around two dozen prescription drugs on Thursday, including the psoriasis treatment Stelara, prostate cancer drug Zytiga and blood thinner Xarelto, all among its top-selling products. J&J joined many other companies that raised U.S. prices on hundreds of prescription medicines earlier this month. Most of the J&J increases were between 6 percent and 7 percent, according to data from Rx Savings Solutions, which helps health plans and employers seek lower cost prescription medicines.

  • Financial Times6 days ago

    [$$] Sanofi and Novo Nordisk press ahead with US insulin prices rises

    have raised prices of insulin in the US, despite political pressure as diabetics protest and lobby lawmakers over the rising cost of the essential medicine. Sanofi increased the price of its three main insulin brands by between 4.4 per cent and 5.2 per cent last week, while Novo Nordisk increased the price of its insulin products by just under 5 per cent on Tuesday. Depending on the dose and brand, the list prices for insulin products vary between $300 and $400.

  • Thoughts on 2018 Performance
    GuruFocus.com8 days ago

    Thoughts on 2018 Performance

    The following is an update on the 2018 performance of individual accounts I run along with the returns of the Hayashi Foundation - a not-for-profit fund based in Japan, of which I am currently chief investment officer. As many of you know, I left Dorfman Value Investments and opened my own investment firm - Nintai Investments LLC - on Oct. 1, 2018. The numbers in this report reflect a composite of fees from both Dorfman and Nintai.

  • Novo Nordisk Boasts Strong Diabetes Presence and Pipeline
    Zacks13 days ago

    Novo Nordisk Boasts Strong Diabetes Presence and Pipeline

    Novo Nordisk (NVO) has a strong presence in the Diabetes Care market and boasts a strong pipeline, with focus on therapeutic proteins within insulin.

  • Benzinga21 days ago

    6 Valuable Pipeline Drugs With Upcoming Catalysts

    Heading into December, biotech stocks held up fairly well in 2018. Evaluate Pharma , a firm specializing in data-driven news and analysis in biotech, compiled a list of blockbuster drugs in the works with ...

  • CNBC25 days ago

    As obesity rates in America soar, new weight loss drugs are in the offing that offer hope

    The average American is nearing the medical definition of obesity, according to new data from the Centers for Disease Control. As many as six new drugs to combat obesity may hit the market in the coming years and improve heart health as well as provide weight-loss benefits. There are more than 97 million people with obesity in the U.S., and that number is set to increase by nearly 3 percent annually on average.

  • Strongbridge completes $181.7M sale of hormone drug to Novo Nordisk
    American City Business Journals28 days ago

    Strongbridge completes $181.7M sale of hormone drug to Novo Nordisk

    The deals include $145 million in cash and the purchase of $36.7 million in Strongbridge stock by Novo Nordisk

  • Here is What Hedge Funds Think About Novo Nordisk A/S (NVO)
    Insider Monkey29 days ago

    Here is What Hedge Funds Think About Novo Nordisk A/S (NVO)

    Billionaire hedge fund managers such as Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the big players […]

  • 3 Biotechs With Potential Blockbusters Near the Finish Line
    Motley Fool29 days ago

    3 Biotechs With Potential Blockbusters Near the Finish Line

    Experimental new drugs at critical stages of development could soon send these stocks screaming in one direction or another.

  • The Wall Street Journallast month

    [$$] Staten Biotechnology Strikes $488 Million Deal With Novo

    Under the partnership, the companies will develop a treatment for hypertriglyceridemia, or high levels of fat in the blood. Staten’s antibody is designed to neutralize apoC3, a key molecule in the management of high lipid levels in the blood, to reduce triglyceride levels, according to the company.

  • Novo Nordisk announces another $22M investment in Clayton
    American City Business Journalslast month

    Novo Nordisk announces another $22M investment in Clayton

    As pharmaceutical production continues to expand in counties east of the Triangle, Novo Nordisk has announced another $22 million expansion of its Clayton facility.

  • Zafgen (ZFGN) Plunges as FDA Puts Hold on Diabetes Drug Trial
    Zacks2 months ago

    Zafgen (ZFGN) Plunges as FDA Puts Hold on Diabetes Drug Trial

    Zafgen's (ZFGN) stock plunges significantly as the FDA placed a clinical hold on the company's first trial on experimental diabetes drug, ZGN-1061.

  • The Zacks Analyst Blog Highlights: Sanofi, Novo Nordisk, NVIDIA, Fifth Third Bancorp and Continental Resources
    Zacks2 months ago

    The Zacks Analyst Blog Highlights: Sanofi, Novo Nordisk, NVIDIA, Fifth Third Bancorp and Continental Resources

    The Zacks Analyst Blog Highlights: Sanofi, Novo Nordisk, NVIDIA, Fifth Third Bancorp and Continental Resources

  • Novo Nordisk A/S (NVO): Hedge Fund Sentiment Going Nowhere
    Insider Monkey2 months ago

    Novo Nordisk A/S (NVO): Hedge Fund Sentiment Going Nowhere

    The government requires hedge funds and wealthy investors with over a certain portfolio size to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings level the playing field for ordinary investors. The latest round of 13F filings discloses the funds’ positions on June […]

  • Novo Nordisk Continues Its Balancing Act
    Motley Fool2 months ago

    Novo Nordisk Continues Its Balancing Act

    Growth on one hand, but declines on the other.

  • Novo Nordisk (NVO) Reports In-Line Q3 Earnings, Beats Sales
    Zacks2 months ago

    Novo Nordisk (NVO) Reports In-Line Q3 Earnings, Beats Sales

    Novo Nordisk (NVO) reports in line earnings in the third quarter of 2018 and announces restructuring plans.

  • The Wall Street Journal2 months ago

    [$$] Danish Insulin Maker Novo Nordisk Cuts Jobs, Shifts R&D Spending

    A/S is cutting costs and reallocating research and development spending as it faces price pressures in the U.S., its biggest market. Four hundred jobs will be eliminated in the company’s research and development unit. Most of the savings in the R&D department will be reinvested in artificial intelligence, cloud services and automation technologies, Mr. Knudsen said.

  • Novo Nordisk (NVO) Q3 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Novo Nordisk (NVO) Q3 2018 Earnings Conference Call Transcript

    NVO earnings call for the period ending September 30, 2018.

  • Upbeat sales lift Novo Nordisk as drugmaker weathers U.S. pricing pressure
    Reuters2 months ago

    Upbeat sales lift Novo Nordisk as drugmaker weathers U.S. pricing pressure

    Novo Nordisk (NOVOb.CO), the world's top maker of diabetes drugs, reported encouraging sales of its main growth drivers on Thursday as it announced more job cuts amid a restructuring to cope with intensifying pricing pressure in the United States. Sales of Novo's new once-weekly Ozempic GLP-1 drug, which the Danish company hopes will take market share from Eli Lilly's (LLY.N) Trulicity, beat forecasts for the third quarter. Eli Lilly has been eating into Novo's previously fast-selling Victoza - a so-called GLP-1 drug that imitates an intestinal hormone to stimulate insulin production.

  • Reuters2 months ago

    Upbeat sales lift Novo Nordisk as drugmaker weathers U.S. pricing pressure

    Novo Nordisk, the world's top maker of diabetes drugs, reported encouraging sales of its main growth drivers on Thursday as it announced more job cuts amid a restructuring to cope with intensifying pricing pressure in the United States. Sales of Novo's new once-weekly Ozempic GLP-1 drug, which the Danish company hopes will take market share from Eli Lilly's Trulicity, beat forecasts for the third quarter. Eli Lilly has been eating into Novo's previously fast-selling Victoza - a so-called GLP-1 drug that imitates an intestinal hormone to stimulate insulin production.

  • Associated Press2 months ago

    Novo Nordisk: 3Q Earnings Snapshot

    On a per-share basis, the Bagsvaerd, Denmark-based company said it had net income of 58 cents. The drugmaker posted revenue of $4.31 billion in the period. Novo Nordisk shares have fallen 19 percent since ...